Search Medical Condition
Please enter condition
Please choose location from dropdown

Additional Locations, Minnesota Clinical Trials

A listing of Additional Locations, Minnesota clinical trials actively recruiting patient volunteers.

RESULTS

Found (1114) clinical trials

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With EZH2 SMARCB1 or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

PRIMARY OBJECTIVES: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with tazemetostat with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas or histiocytic disorders that harbor gain of function mutations in EZH2, or loss of function mutations in the ...

Phase

1.24 miles

Learn More »

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent Refractory or Newly Diagnosed Sarcomas Wilms Tumor or Other Rare Tumors

PRIMARY OBJECTIVES: I. To determine the objective response rate (complete response + partial response) of cabozantinib-s-malate (XL184) in children and young adults. II. To estimate whether XL184 therapy either improves the disease control rate at 4 months in patients with recurrent measurable osteosarcoma as compared to a historical Childrens Oncology ...

Phase

1.24 miles

Learn More »

Developmental Impact of NICU Exposures (DINE)

Background: Each year in the United States, over 300,000 preterm infants are admitted to neonatal intensive care units (NICUs) where they are exposed to a chemical-intensive hospital environment during a developmentally vulnerable period. Many life-saving and supportive respiratory, nutritional, hematologic and pharmaceutical therapies in the NICU expose preterm infants to ...

Phase N/A

1.24 miles

Learn More »

Childhood Cancer Survivor Study

The study will focus on the following objectives: Characterize survivors' health with respect to disease- and treatment-related factors. Investigate the consequences of various intensities of exposure to chemotherapy and/or radiation on health outcomes (e.g., cardiovascular, reproductive, second cancers, etc). Compare the mortality experience of survivors with the general population. Characterize ...

Phase N/A

1.24 miles

Learn More »

International Ovarian & Testicular Stromal Tumor Registry

The Registry collects and analyzes case-by-case data on ovarian stromal tumors. Cases are identified by referrals from clinicians or pathologists by families initiating contact with the Registry by Registry requests to authors of published cases to share further details The data collected include: clinical and laboratory findings family history imaging ...

Phase N/A

1.24 miles

Learn More »

Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs

This study will evaluate local pediatric intensive care unit (PICU), cardiac intensive care unit (CICU) and neonatal intensive care unit (NICU) as well as EDs and delivery room (DR) practice, and benchmark against other PICUs, CICUs, NICUs, DRs and EDs as a part of Multi-Center Airway Safety collaborative network (NEAR4KIDS). ...

Phase N/A

1.24 miles

Learn More »

Vincristine Sulfate Liposome Injection (Marqibo ) in Combination With UK ALL R3 Induction Chemotherapy for Children Adolescents and Young Adults With Relapsed ALL

This study will utilize Marqibo as a replacement for standard vincristine in combination with UK ALL R3 induction for children with relapsed ALL. The hypothesis is that the incorporation of Marqibo with combination chemotherapy will be safe and feasible. In the context of this pilot study, overall outcomes and efficacy ...

Phase

1.24 miles

Learn More »

Phase 2 Study of Glesatinib Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Glesatinib is an orally administered multi-targeted tyrosine kinase inhibitor (TKI) that primarily targets the Axl and Mesenchymal-Epithelial Transition (MET) receptors. Sitravatinib is an orally-available, potent small molecule inhibitor of a closely related spectrum of receptor tyrosine kinases (RTKs) including MET, Axl, MERTK, VEGFR family, PDGFR family, KIT, FLT3, Trk family, ...

Phase

1.24 miles

Learn More »

A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Phase

1.24 miles

Learn More »

Study of Nivolumab Plus Ipilimumab Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to determine whether Nivolumab plus Ipilimumab has preliminary evidence of safety and effectiveness in the treatment of participants with metastatic castration-resistant prostate cancer who have progressed after prior Docetaxel-containing regimen.

Phase

1.24 miles

Learn More »